Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders. Headquartered in Rockville, Maryland, the company’s portfolio targets epilepsy, Parkinson’s disease and attention‐deficit/hyperactivity disorder (ADHD), among other neurological conditions.
Among its marketed products, Supernus offers Trokendi XR, an extended‐release formulation of topiramate for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures, and Oxtellar XR, an extended‐release version of oxcarbazepine for partial-onset seizures. The company also commercialized Xadago (safinamide) in the U.S. under license from BIAL for adjunctive treatment in Parkinson’s disease and launched Qelbree (viloxazine) capsules for pediatric and adult ADHD patients.
Supernus maintains a robust research and development pipeline with several CNS-focused candidates in various stages of clinical trials. Key investigational programs include SPN-830 for amyotrophic lateral sclerosis (ALS) and SPN-812, a non-stimulant ADHD therapy in late-stage development. The company’s R&D efforts are complemented by strategic partnerships and licensing agreements designed to expand its product offerings and address unmet medical needs in neurology.
Founded in 2002, Supernus went public in 2014 and has since grown its U.S. commercial operations through a dedicated sales force and specialty pharmacy channels. The company is led by President and Chief Executive Officer Paul Hastings, supported by a management team with expertise in R&D, regulatory affairs and commercial strategy. While its primary market remains the United States, Supernus continues to explore opportunities for international expansion through collaborations and licensing arrangements.
AI Generated. May Contain Errors.
